0001661181-18-000035.txt : 20181212 0001661181-18-000035.hdr.sgml : 20181212 20181212194611 ACCESSION NUMBER: 0001661181-18-000035 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181210 FILED AS OF DATE: 20181212 DATE AS OF CHANGE: 20181212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bilbo Patrick CENTRAL INDEX KEY: 0001759203 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37906 FILM NUMBER: 181231893 MAIL ADDRESS: STREET 1: C/O ORGANOGENESIS INC. STREET 2: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Organogenesis Holdings Inc. CENTRAL INDEX KEY: 0001661181 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 BUSINESS PHONE: 781-575-0775 MAIL ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 FORMER COMPANY: FORMER CONFORMED NAME: Avista Healthcare Public Acquisition Corp. DATE OF NAME CHANGE: 20151215 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-12-10 0001661181 Organogenesis Holdings Inc. ORGO 0001759203 Bilbo Patrick C/O ORGANOGENESIS HOLDINGS INC. 85 DAN ROAD CANTON MA 02021 0 1 0 0 Chief Operating Officer Common Stock 2018-12-10 4 A 0 121800 A 121800 D Stock Option (Right to Buy) 1.44 2018-12-10 4 A 0 30450 A 2021-12-06 Common Stock 30450 30450 D Stock Option (Right to Buy) 1.18 2018-12-10 4 A 0 152250 A 2024-04-10 Common Stock 152250 152250 D Stock Option (Right to Buy) 3.46 2018-12-10 4 A 0 142100 A 2027-05-04 Common Stock 142100 142100 D Stock Option (Right to Buy) 3.46 2018-12-10 4 A 0 101500 A 2027-05-04 Common Stock 101500 101500 D Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for 60,000 shares of common stock of Organogenesis. 100% of the shares subject to this option are fully vested and exercisable. Received in connection with the Merger in exchange for an option to acquire 15,000 shares of common stock of Organogenesis for $2.92 per share. The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2015. Received in connection with the Merger in exchange for an option to acquire 75,000 shares of common stock of Organogenesis for $2.38 per share. The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017. Received in connection with the Merger in exchange for an option to acquire 70,000 shares of common stock of Organogenesis for $7.01 per share. The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018. Received in connection with the Merger in exchange for an option to acquire 50,000 shares of common stock of Organogenesis for $7.01 per share. /s/ Stacie S. Aarestad, Attorney-in-Fact 2018-12-12